Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ikena Oncology, Inc. (IKNA : NSDQ)
 
 • Company Description   
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.

Number of Employees: 67

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.57 Daily Weekly Monthly
20 Day Moving Average: 234,712 shares
Shares Outstanding: 36.11 (millions)
Market Capitalization: $128.91 (millions)
Beta: 1.26
52 Week High: $21.18
52 Week Low: $2.83
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -38.13% -30.32%
12 Week -49.22% -44.18%
Year To Date -71.53% -63.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
645 SUMMER STREET SUITE 101
-
BOSTON,MA 02210
USA
ph: 857-273-8343
fax: -
rcohen@ikenaoncology.com None
 
 • General Corporate Information   
Officers
Mark Manfredi - Chief Executive Officer; President; Principal Fina
Francisco Oliveira - Vice President of Finance and Administration Princ
Ron Renaud - Director
David Bonita - Director
Iain D. Dukes - Director

Peer Information
Ikena Oncology, Inc. (CORR.)
Ikena Oncology, Inc. (RSPI)
Ikena Oncology, Inc. (CGXP)
Ikena Oncology, Inc. (BGEN)
Ikena Oncology, Inc. (GTBP)
Ikena Oncology, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45175G108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 36.11
Most Recent Split Date: (:1)
Beta: 1.26
Market Capitalization: $128.91 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.83 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.67
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 81.35%
vs. Previous Quarter: -771.43%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -83.26%
ROE
03/31/22 - -20.11
12/31/21 - -15.96
09/30/21 - -46.12
ROA
03/31/22 - -16.23
12/31/21 - -12.61
09/30/21 - -25.12
Current Ratio
03/31/22 - 8.53
12/31/21 - 8.70
09/30/21 - 8.24
Quick Ratio
03/31/22 - 8.53
12/31/21 - 8.70
09/30/21 - 8.24
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -150.79
12/31/21 - -110.10
09/30/21 - -1,652.14
Book Value
03/31/22 - 5.34
12/31/21 - 5.78
09/30/21 - 5.67
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©